Company intelligence / Profile preview

MediKane

Ownership: Private
Development stage: Commercial

Overview

MediKane’s NutriKane range has undergone scientific and clinical trials demonstrating benefits for blood sugar regulation, gut health, inflammation reduction, pancreatic function, and overall chronic condition management. Clinical studies have been conducted at institutions such as Macquarie University and the Kolling Institute – Sydney University. Products have peer-reviewed validation for efficacy with no reported side effects.

Therapeutic areas: OtherEndocrinologyGastroenterology
Modalities: Non-pharmacological therapyFood-as-Medicine productPlant-based natural product
Industry: Food & Nutrition

Drug pipeline

2 assets

NutriKane D

Commercial

Indications: Diabetes, Blood glucose management

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on MediKane.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MediKane.

Explore the full profile